



03-02-07

IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/589,688 ✓
	Filing Date	August 17, 2006
	First Named Inventor	Mark Greene
	Art Unit	To be Determined
	Examiner Name	To be Determined
Total Number of Pages in This Submission	Attorney Docket Number	UPN0017-100 (P3086)

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached/Authorized <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO SB/08a and SB/08b(5pp.); 53 reference cited; 37 copies of references submitted; return card.
Remarks EXPRESS MAIL LABEL NO: EV 770972302 US DATE OF DEPOSIT: February 28, 2007		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Cozen O'Connor		
Signature			
Printed Name	Mark DeLuca		
Date	February 28, 2007	Reg. No.	33,229

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IPN0017-100 (P3086)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: **Mark I. Greene et al.**

Serial No.: **10/589,688**

Group Art Unit: **To be determined**

Filed: **August 17, 2006**

Examiner: **To be determined**

Title: **BINDING PEPTIDOMIMETICS AND USES OF THE SAME**

EXPRESS MAIL LABEL NO: EV 770972302 US

DATE OF DEPOSIT : February 28, 2007

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and Forms SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.

- ☐ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
- ☐ the Statement under 37 C.F.R. § 1.97(e) (see “Statement” below);
- or**
- ☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
- ☐ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see “Statement” below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see “Statement,” and “Fees” below).
- ☒ Copies of the references (except the U.S. Patent documents) listed on the attached PTO Forms SB/08a and SB/08b, formerly known as PTO Form 1449, are enclosed.

EXCEPT THAT:

- ☐ In view of the voluminous nature of references ____, and the likelihood that this reference is available to the Examiner, a copy is not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Fees

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☒ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,



Mark DeLuca
Registration No. 33,229

Dated: February 28, 2007

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-2000 - Telephone
(215) 665-2013 - Facsimile

PTO/SB/08A (07-05)



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	10/589,688
Filing Date	August 17, 2006
First Named Inventor	Mark Greene
Art Unit	To be Determined
Examiner Name	To be Determined
Attorney Docket Number	UPN0017-100 (P3086)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AQ	Argarana, et al., "Molecular cloning and nucleotide sequence of the streptavidin gene," <i>Nucleic Acids Res.</i> (1986), 14 (4): 1871-1882.	
	AR	Chirinos-Rojas, C.L. et al., "A peptidomimetic antagonist of TNF-alpha-mediated cytotoxicity identified from a phage-displayed random peptide library," <i>J Immunol.</i> (1998), 161(10):5621-6	
	AS	Dubel, S. et al., "Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv).," <i>J Immunol Methods</i> (1995), 178(2):201-9.	
	AT	Felix, A.M., "Applications of BOP reagent in solid phase synthesis", <i>Int. J. Pep. Prot. Res.</i> 1988 31:231-238.	
	AU	Giralt, E. and Andreu eds, <i>In Peptides</i> , ESCOM, Leiden, The Netherlands 1991,131-133.	
	AV	Hruby, "Conformational restrictions of biologically active peptides via amino acid side chain groups," <i>Life Sci.</i> (1982) 31: 189-199.	
	AW	Karp, et al., "Identification of biotinylated molecules using a baculovirus-expressed luciferase-streptavidin fusion protein," <i>Biotechniques</i> (1996), 20 (3): 452-456, 458-459.	
	AX	Kipriyanov, et al., "Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion," <i>Protein Eng.</i> (1996), 9 (2): 203-211.	
	AY	Kipriyanov, et al., "Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen," <i>Hum. Antibodies Hybridomas</i> (1995), 6 (3): 93-101.	
	AZ	Kishore et al., "A recombinant homotrimer, composed of the alpha helical neck region of human surfactant protein D and C1q B chain globular domain, is an inhibitor of the classical complement pathway," <i>J. Immunol</i> (2001) 166: 559-565.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/589,688
Filing Date	August 17, 2006
First Named Inventor	Mark Greene
Art Unit	To be Determined
Examiner Name	To be Determined
Attorney Docket Number	UPN0017-100 (P3086)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BA	Koo, et al., "Development of a streptavidin-conjugated single-chain antibody that binds <i>Bacillus cereus</i> spores," <i>Applied Environ. Microbiol.</i> (1998), 64 (7): 2497-2502.	
	BB	Le, et al., "A streptavidin-cellulose-binding domain fusion protein that binds biotinylated proteins to cellulose," <i>Enzyme Microb. Technol.</i> 16 (6): 496-500, 1994	
	BC	Lee, W. et al., "Solution structure of the tetrameric minimum transforming domain of p53," <i>Nature Struct. Biol.</i> (1994), 1: 877-890.	
	BD	Murali et al., "Structure-based design of immunologically active therapeutic peptides," <i>Immunol. Res.</i> (1998) 17: 163-169.	
	BE	Ohno and Meruelo, "Multi-drug delivery system using streptavidin-transforming growth factor-alpha chimeric protein," <i>DNA Cell Biol.</i> (1996), 15 (5): 401-406.	
	BF	Ohno, et al., "Cell-specific, multidrug delivery system using streptavidin-protein A fusion protein," <i>Biochem. Mol. Med.</i> (1996) 58 (2): 227-233.	
	BG	Pearce, et al. "Linear gene fusions of antibody fragments with streptavidin can be linked to biotin labelled secondary molecules to form bispecific reagents," <i>Biochem. Mol. Biol. Int.</i> (1997) 42 (6): 1179-1188.	
	BH	Ploux, O. et al., "Cyclization of peptides on a solid support. Application to cyclic analogs of substance P," <i>Int. J. Pep. Prot. Res.</i> (1987), 29: 162-169.	
	BI	Porstmann, T. et al., "Enzyme immunoassay techniques. An overview," <i>J Immunol Methods.</i> (1992), 150(1-2):5-21.	
	BJ	Porstmann, B. et al., "Which of the commonly used marker enzymes gives the best results in colorimetric and fluorimetric enzyme immunoassays: horseradish peroxidase, alkaline phosphatase or beta-galactosidase?" <i>J Immunol Methods</i> (1985), 79(1):27-37.	
	BK	Prasad et al., "Contrasting solution conformations of peptides containing alpha, alpha-dialkylated residues with linear and cyclic side chains," <i>Biopolymers</i> (1995) 35: 11-20.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Institute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number	10/589,688
Filing Date	August 17, 2006
First Named Inventor	Mark Greene
Art Unit	To be Determined
Examiner Name	To be Determined
Attorney Docket Number	UPN0017-100 (P3086)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BL	Rogers et al., "Characterization of disulfide crosslink formation of human vimentin at the dimer, tetramer, and intermediate filament levels," <i>J Struct Biol.</i> (1996) Jul-Aug ; 117 (1) : 55-69	
	BM	Roland J. et al., "The synthetic CD4 exocyclic CDR3.AME(82-89) inhibits NF-kappaB nuclear translocation, HIV-1 promoter activation, and viral gene expression," <i>DNA Cell Biol.</i> (1999), Nov;18(11):819-28.	
	BN	Romani, S. et al., "Synthesis of the trypsin fragment 10-25/75-88 of mouse nerve growth factor. II. The unsymmetrical double chain cystine peptide," <i>Int. J. Pep. Prot. Res.</i> (1987), 29: 107-117	
	BO	Sano and Cantor, "Expression of a cloned streptavidin gene in Escherichia coli," <i>Proc. Natl. Acad. Sci. USA</i> (1990), 87 (1) : 142-146.	
	BP	Sano and Cantor, "A streptavidin-protein A chimera that allows one-step production of a variety of specific antibody conjugates," <i>Biotechnology</i> (1991), 1378-1381.	
	BQ	Sano and Cantor, "Expression vectors for streptavidin-containing chimeric proteins," <i>Biochem.Biophys. Res. Commun</i> (1991), 176 (2): 571-577.	
	BR	Sano et al., "A streptavidin-metallothionein chimera that allows specific labeling of biological materials with many different heavy metal ions," <i>Proc. Natl. Acad. Sci. USA</i> (1998), 89 (5): 1534-1538.	
	BS	Saragovi et al., "Design and synthesis of a mimetic from an antibody complementarity-determining region," <i>Science</i> (1991), 253: 792-795.	
	BT	Schiller et al., "Synthesis of side-chain to side-chain cyclized peptide analogs on solid supports," <i>Int. J. Pep. Prot. Res.</i> (1985), 25: 171-177.	
	BU	Schweitzer et al., "Inaugural article: immunoassays with rolling circle DNA amplification: a versatile platform for ultrasensitive antigen detection," <i>Proc Natl Acad Sci U S A.</i> (2000), 97(18):10113-9.	
	BV	Sheppard, R. C., "Acid-labile resin linkage agents for use in solid phase peptide synthesis," <i>Int. J. Peptide Res.</i> (1982), 20: 451-454.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	10/589,688
Filing Date	August 17, 2006
First Named Inventor	Mark Greene
Art Unit	To be Determined
Examiner Name	To be Determined
Attorney Docket Number	UPN0017-100 (P3086)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BW	Srinivasan, M. et al., "Immunomodulatory peptides from IgSF proteins: a review," <i>Curr Protein Pept Sci.</i> (2005), 6(2):185-96.	
	BX	Tannous et al., "T7 RNA polymerase as a self-replicating label for antigen quantification," <i>Nucleic Acids Res</i> (2002), 30(24):e140.	
	BY	Walsh and Swaisgood, "An <i>Escherichia coli</i> plasmid vector system for production of streptavidin fusion proteins: Expression and bioselective adsorption of streptavidin- β -galactosidase," <i>Biotech. Bioeng.</i> (1994) 44: 1348-1354.	
	BZ	Williams et al., "Development of biologically active peptides based on antibody structure," <i>Proc. Natl Acad. Sci. USA</i> (1989), 86: 5537-5541.	
	CA	Zhang X. et al., "Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes," <i>Nat Biotechnol.</i> (1997), 15(2):150-4.	
	CB	Zhang et al., "Crystal structure of recombinant human platelet factor 4," <i>Biochem</i> (1994), V33: 8361-8366.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.